Search the Newsreel

Why Taseko Mines Ltd stock is rising today

Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN

Editas Medicine, Inc. reported a net loss of $18.2M and revenues of $11.9M for Q2 2026, with cash reserves sufficient until H2 2028. The company is advancing its EDIT-401 program by filing an Australian CTN to initiate a Phase 1/2 trial for HeFH in …

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Raised 2026 Earnings Outlook On Senior Housing Strength Might Change The Case For Investing In Ventas (VTR)

Ventas (VTR) recently reported Q2 2026 results, showing revenue of US$1.73 billion and net income of US$70.57 million. The company modestly raised its full-year 2026 attributable net income per share guidance, attributing this increased confidence to strong senior housing operating performance and planned investments …

VESTAS WIND SYSTEMS A-S AKTIE: AI-Analysen, Prognose & Kursziel

Royal Bank of Canada Has $9.75 Million Stock Holdings in Taseko Mines Limited $TGB

Cintas Earns Place on U.S. News & World Report’s List of 2026-2027 Best Companies to Work For

Cintas Corporation has been recognized by U.S. News & World Report as one of the 2026-2027 Best Companies to Work For, marking its second consecutive year receiving this honor. The recognition is based on an evaluation of 3,900 organizations across various categories, with Cintas …

Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Taseko Mines Q2 Earnings Call Highlights

Airtasker (ASX:ART): Can International Expansion Reshape Its Growth Story?

Adveritas (ASX:AV1) Hits A$16.3 Million in Recurring Revenue as TrafficGuard Finds a New Small-Business Growth Engine

Navitas Semiconductor (NVTS) Is Up 27.9% After Guiding For A Q3 Revenue Rebound And Y/Y Growth

Galantas Gold triples Indiana drill campaign on new mineralization indications

Datasea Expands Acoustic AI Healthcare Robot Partnership To Accelerate Commercial Deployment

Datasea Inc. announced an expanded partnership with Yizhimei Technology Co., Ltd. to accelerate the commercial deployment of acoustic + AI head-care robots for health and wellness. This collaboration transitions from technology enablement to product commercialization and market expansion, targeting over 4,500 locations globally, building …

Cintas (CTAS) Names Jim Rozakis President

Cintas (NasdaqGS: CTAS) has announced a leadership change, appointing Jim Rozakis as President while Todd Schneider remains CEO, formally separating the two roles. This move signals a new executive structure for the company, aiming to clarify the split between high-level direction and day-to-day operations …

Intrepid Potash Q2 Earnings Call Highlights

Key Points Interested in Intrepid Potash, Inc? Here are five stocks we like better. Profitability improved in Q2: Adjusted EBITDA rose to $17.5 million from $13.8 million, while gross margin increased 35% to $16.6 million, driven by stronger Trio margins and improved potash operations. …

Stratasys Ltd (SSYS) Stock News Today

This article provides current stock information for Stratasys Ltd (SSYS), including its market price, market cap, and P/E TTM. It indicates that more news, earnings, and analyst ratings are expected soon for the company. The article

Gradient Investments LLC Grows Position in Cintas Corporation $CTAS

Gradient Investments LLC increased its stake in Cintas Corporation (NASDAQ:CTAS) by 21.8% in the second quarter, bringing its total holding to $21.56 million. Institutional investors now own 63.46% of the company. Cintas exceeded earnings expectations, with strong revenue growth, and analysts maintain a "Moderate …

Cintas Corporation $CTAS Shares Bought by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Cintas Corporation (NASDAQ:CTAS) by 8.7% in the second quarter, bringing its total holdings to 69,891 shares valued at approximately $11.9 million. Cintas has exceeded quarterly expectations with $1.29 adjusted EPS and $2.91 billion in revenue, and has issued …

Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold

Wall Street Zen has upgraded Editas Medicine (NASDAQ:EDIT) from "sell" to "hold." Despite this, broader analyst coverage remains "Moderate Buy" with a consensus price target of $5.40. The company recently surpassed quarterly earnings and revenue expectations, although company insiders have sold shares while institutional …

Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement

Editas Medicine director Ellinor Patrick Thomas II has filed an initial beneficial ownership statement (Form 3) with the SEC, dated August 6. This filing indicates that Thomas is now a reporting owner for the company. The news brief was generated by Public Technologies (PUBT) …

BESIKTAS FUTBOL - KAP Haberleri - 2026-08-07 tarihli

Navitas Semiconductor Corp (NVTS) Stock Analysis & Forecast

This article provides an analysis of Navitas Semiconductor Corp (NVTS) stock, highlighting its strategic pivot from consumer charging to AI data centers and grid infrastructure. Despite near-term volatility and market shifts, the company has seen significant stock rallies. The analysis also briefly touches upon …

Is Cintas (CTAS) Fairly Valued After Its Leadership Reshuffle?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cintas (CTAS) recently drew investor attention after separating the roles of president and chief executive officer and appointing Jim Rozakis as president and COO, …

Taskus Inc (TASK) Stock News Today

Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000

Editas Medicine (NASDAQ: EDIT) reported that director Ellinor Patrick Thomas II was granted 103,400 stock options with an exercise price of $2.9000 per share, expiring on August 5, 2036. These options vest in three equal annual installments starting August 6, 2027. Following this grant, …

Editas Medicine, Inc. (EDIT) director reports no share or option holdings

A director at Editas Medicine, Inc. (EDIT), Ellinor Patrick Thomas II, has filed an initial beneficial ownership report (Form 3) disclosing no holdings of common stock or derivative securities. The filing indicates no insider transaction activity, such as purchases or sales, associated with this …

Stratasys Ltd (SSYS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Stratasys Ltd (SSYS) has an earnings forecast score of 7.50, ranking 35th in its industry, with an average price target of $13.50. Analysts largely recommend a "Buy" for the stock, expecting next quarter's revenue to be $138.48 million and EPS to be $0.01.

Alpargatas (ALPA4): ação salta mais de 10% após resultados do 2T; veja destaques

Cintas (CTAS) Splits President And CEO Roles As Jim Rozakis Takes Operations

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Cintas (NasdaqGS: CTAS) has separated the President and CEO roles, with Jim Rozakis appointed President and COO while Todd Schneider remains CEO. The …

Editas Medicine (EDIT) Stock Rallies On Revenue Jump But Losses Linger

Editas Medicine (EDIT) saw its stock rally by about 5% after reporting Q2 2026 earnings, driven by a significant increase in revenue to US$11.89 million from US$3.58 million year-on-year. While the company is still reporting losses, these narrowed to US$18.23 million from US$53.24 million, …

Datasea Inc (DTSS) Stock News Today

This article from TradingKey provides current stock information for Datasea Inc (DTSS). It details the stock's closing price, market capitalization, and indicates that more news, earnings reports, analyst ratings, and key developments will be available soon.

Ventas Inc (VEN) Q2 2023 Earnings Report - Results, Call & Slides

Ventas Inc. (VEN) reported its Q2 2023 earnings, beating analyst expectations for both EPS and revenue. The company announced an actual EPS of CHF0.21 against a consensus of CHF0.02, and actual revenue of CHF893.96M compared to an expected CHF881.06M, marking an 8.15% year-over-year revenue …

Cintas (CTAS) Just Overtook the 20-Day Moving Average

After reaching an important support level, Cintas (CTAS) could be a good stock pick from a technical perspective. CTAS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a well-liked trading tool because it provides …

Assenagon Asset Management S.A. Has $207.09 Million Stock Position in Cintas Corporation $CTAS

Assenagon Asset Management S.A. significantly increased its stake in Cintas Corporation, now holding 1.22 million shares valued at $207.09 million. Cintas continues to impress with strong earnings and revenue growth, beating analyst expectations and increasing its quarterly dividend. The company maintains a "Moderate Buy" …

NVTS Stock Pops As AI Power Pivot Drives Bullish Guidance

Navitas Semiconductor (NVTS) stock surged over 9% following better-than-expected Q3 revenue guidance and a strategic pivot towards high-power GaN and SiC markets driven by AI data centers. The "Navitas 2.0" plan focuses on high-value AI infrastructure, which is projected to exceed one-third of sales …